£50m UK centre to overhaul clinical trial design
A new UK initiative aims to shake-up approaches to clinical trial design and delivery by developing new ways to speed up the process and drive improvements.
The Medical Research Council Centre of Research Excellence in Clinical Trial Innovation in partnership with the National Institute for Health and Care Research will receive up to £50 million over 14 years with the ambition of transforming the clinical trial landscape.
One of the centre’s key areas of focus will be to move away from the current approach of testing a single intervention in a single disease one at a time and develop new efficient ways to test multiple drugs in multiple diseases simultaneously.
Another significant area of focus is using clinical trials to identify minimum ‘intensity’ such as duration, frequency, or dose required for a drug to be effective, i.e., finding the lowest effective dose of a chemotherapy drug, which could reduce side effects.
Professor Patrick Chinnery, Medical Research Council Executive Chair, explained: “It is essential to quickly move such interventions forward to the right patients, at the right doses, durations and combinations. The MRC is delighted to be supporting this new methodology-focused CoRE towards faster patient impact of our research, especially with their plans to address underserved areas such as multiple long-term conditions and rare diseases.”
The centre will be led by Professor Max Parmar. He added: “Basic science is rapidly producing more understanding of biology and consequently many new interventions to help us in a range of diseases – both by industry and academic routes. We plan for this to act as a hub for ground-breaking developments in clinical trial methodology.”
The CoRE will work with researchers, doctors, statisticians, drug companies and regulatory bodies both to develop and implement new trial designs.
Diana Turner, Deputy Editor, DDW
